These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention. Feldman DN; Wong SC; Bergman G; Minutello RM J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400 [TBL] [Abstract][Full Text] [Related]
7. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy. Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ; J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319 [TBL] [Abstract][Full Text] [Related]
8. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152 [TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction. Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986 [TBL] [Abstract][Full Text] [Related]
10. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ; JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903 [TBL] [Abstract][Full Text] [Related]
11. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845 [TBL] [Abstract][Full Text] [Related]
12. Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions. Kao J; Lincoff AM; Topol EJ; Madrid A; J Price M; Sawhney N; Teirstein PS Catheter Cardiovasc Interv; 2006 Sep; 68(3):352-6. PubMed ID: 16892428 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice. Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573 [TBL] [Abstract][Full Text] [Related]
16. Head-to-head comparison of bivalirudin versus heparin without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing primary angioplasty. Bonello L; de Labriolle A; Roy P; Steinberg DH; Pinto Slottow TL; Xue Z; Kaneshige K; Torguson R; Suddath WO; Satler LF; Kent KM; Pichard AD; Waksman R Cardiovasc Revasc Med; 2009; 10(3):156-61. PubMed ID: 19595396 [TBL] [Abstract][Full Text] [Related]
17. Bivalirudin versus unfractionated heparin in patients undergoing percutaneous coronary intervention after acute myocardial infarction. Chu WW; Kuchulakanti PK; Wang B; Torguson R; Clavijo LC; Pichard AD; Suddath WO; Satler LF; Kent KM; Waksman R Cardiovasc Revasc Med; 2006; 7(3):132-5. PubMed ID: 16945819 [TBL] [Abstract][Full Text] [Related]
18. Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. Exaire JE; Butman SM; Ebrahimi R; Kleiman NS; Harrington RA; Schweiger MJ; Bittl JA; Wolski K; Topol EJ; Lincoff AM; Am Heart J; 2006 Jul; 152(1):157-63. PubMed ID: 16824849 [TBL] [Abstract][Full Text] [Related]